Hence, we confirm previous studies in that EGFR (over)expression is not a feasible predictive marker for EGFR-targeted therapy, quite in contrast to what is seen for e.g. HER2-targeted therapy in breast cancers [42]. The gene discussed is EGFR; the disease is breast carcinoma.